Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Rebamipide kontra Diquafosol og Cyclosporine for perioperativt tørr øye ved kataraktkirurgi

16. november 2026 oppdatert av: Dong Hui Lim, Samsung Medical Center

Rebamipide kontra Diquafosol-Cyclosporin for perioperativ tørr øyesykdom ved kataraktkirurgi: En randomisert studie

The goal of this clinical trial is to compare the efficacy of 2% rebamipide monotherapy versus a combination therapy of 3% diquafosol and 0.05% cyclosporine for the management of dry eye disease in patients undergoing cataract surgery. It will also evaluate the safety and ocular surface stability effects of these treatments during the perioperative period.

The main questions it aims to answer are:

Does rebamipide monotherapy maintain tear film breakup time (TBUT) and prevent corneal damage as effectively as the combination therapy after surgery? How do patient symptoms (OSDI scores) and inflammation markers (MMP-9) change with each treatment?

Researchers will compare the rebamipide group to the diquafosol-cyclosporine combination group to evaluate their effects on perioperative dry eye management.

Participants will:

Use the assigned study eye drops starting 1 month before their cataract surgery and continuing for 3 months after surgery.

Visit the clinic for eye examinations at baseline, the day of surgery, and at 1 week, 1 month, and 3 months postoperatively.

Undergo tests including tear film breakup time measurement, corneal staining, Schirmer's test, and tear MMP-9 level assessments.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Dry eye disease (DED) is common in patients undergoing cataract surgery and may worsen during the perioperative period, leading to ocular discomfort and delayed visual recovery. Pharmacologic treatments targeting tear film instability and ocular surface inflammation are therefore important in perioperative management.

This prospective, randomized, parallel-group clinical trial compared two perioperative treatment strategies for DED in patients scheduled for cataract surgery. Eligible participants with pre-existing dry eye disease were randomized in a 1:1 ratio to receive either topical rebamipide 2% monotherapy or combination therapy with topical diquafosol 3% and cyclosporine 0.05%. Study medications were initiated 1 month prior to surgery and continued for 3 months postoperatively.

The primary outcome measure was the change in tear film breakup time (TBUT) during the early postoperative period. Secondary outcome measures included changes in corneal staining graded by the Oxford scale, patient-reported symptoms assessed by the Ocular Surface Disease Index (OSDI), tear secretion measured by Schirmer's test, and ocular surface inflammation evaluated using a tear matrix metalloproteinase-9 (MMP-9) point-of-care immunoassay.

Clinical assessments were performed at baseline, on the day of surgery, and at postoperative week 1, month 1, and month 3. Safety was evaluated by monitoring intraoperative and postoperative adverse events throughout the study period.

Studietype

Intervensjonell

Registrering (Faktiske)

56

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Seoul
      • Seoul, Seoul, Sør -Korea
        • Samsung Medical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Adults scheduled for cataract surgery

  • Presence of dry eye disease, defined as an Ocular Surface Disease Index (OSDI) score ≥12 and at least one of the following:

    • Tear film breakup time (TBUT) ≤7 seconds
    • Oxford corneal staining grade ≥1
    • Schirmer's test value ≤10 mm/5 min
  • Ability and willingness to comply with the study protocol and follow-up schedule

  • Provision of written informed consent

Exclusion Criteria:

  • Presence of ocular surface or ocular conditions that could affect dry eye status (e.g., active keratitis or ocular infection)
  • Use of topical intraocular pressure-lowering medications
  • History of ocular surgery other than cataract surgery in the study eye
  • Any systemic or ocular condition judged by the investigator to interfere with study participation or outcome assessment

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Group R

Participants receive topical rebamipide 2% ophthalmic solution four times daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively.

Topical administration, four times daily

Aktiv komparator: Group DC

Participants receive topical diquafosol 3% ophthalmic solution four times daily in combination with cyclosporine 0.05% ophthalmic solution twice daily, initiated 1 month before cataract surgery and continued for 3 months postoperatively.

Topical administration, four times daily

Topical administration, two times daily

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Tear Film Breakup Time (TBUT)
Tidsramme: From baseline to postoperative week 1

Change in tear film breakup time (TBUT) from baseline and during the early postoperative period following cataract surgery, comparing rebamipide monotherapy with diquafosol-cyclosporine combination therapy.

From baseline to postoperative week 1

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Ocular Surface Disease Index (OSDI) Score
Tidsramme: From baseline to 1 and 3 months postoperatively

Change in patient-reported ocular symptoms assessed using the Ocular Surface Disease Index (OSDI) questionnaire, comparing rebamipide monotherapy with diquafosol-cyclosporine combination therapy. The OSDI score ranges from 0 to 100, with higher scores indicating more severe ocular surface symptoms (worse outcomes).

From baseline to 1 and 3 months postoperatively
Change in Corneal Staining Grade (Oxford Scale)
Tidsramme: From baseline to postoperative week 1, and to 1 and 3 months postoperatively

Change in corneal epithelial staining graded using the Oxford grading scale (0-5) following fluorescein staining, comparing ocular surface staining severity between treatment groups. Higher grades indicate more severe corneal epithelial staining (worse outcomes).

From baseline to postoperative week 1, and to 1 and 3 months postoperatively
Change in Schirmer's Test Value
Tidsramme: From baseline to 1 and 3 months postoperatively

Change in tear secretion measured by Schirmer's test without anesthesia, comparing tear production between rebamipide monotherapy and diquafosol-cyclosporine combination therapy.

From baseline to 1 and 3 months postoperatively
Change in Tear Matrix Metalloproteinase-9 (MMP-9) Level
Tidsramme: From baseline to 1 and 3 months postoperatively

Change in tear matrix metalloproteinase-9 (MMP-9) levels assessed using a point-of-care immunoassay (InflammaDry), comparing ocular surface inflammation between treatment groups.

From baseline to 1 and 3 months postoperatively

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. august 2025

Primær fullføring (Faktiske)

1. mai 2026

Studiet fullført (Faktiske)

1. mai 2026

Datoer for studieregistrering

Først innsendt

2. februar 2026

Først innsendt som oppfylte QC-kriteriene

2. februar 2026

Først lagt ut (Faktiske)

9. februar 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

16. november 2026

Sist bekreftet

1. februar 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • SMC RVK Trial I

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

The detailed study protocol and the data that support the findings of this study are available from the corresponding author upon reasonable request.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .